Tell us what you think about the NIHR policy on trial registration and disclosure of trial results

Draft NIHR WHO statement policy
Prospective study registration and timely disclosure of results are important for ethical, moral, accountability, research integrity and waste reduction perspectives. As a public funder of research involving patients and the public, these are particularly important perspectives to us and our research communities. Much of NIHR research and the researchers that deliver it uphold the highest standards of transparency and do register and publish their results. The NIHR cares about issues relating to research integrity, waste reduction and transparency, and works to improve the quality and impact of research (for example see the NIHR Adding Value in Research framework).
One part of that work has been to sign-up to the World Health Organisation (WHO) Joint statement on public disclosure of results from clinical trials.
In order to deliver on that commitment we are required to develop a policy describing our expectations and practical support for our research communities to comply. To that end a draft policy on prospective trial registration and timely disclosure of Clinical Trial results was released on the 8 August 2018.

PLEASE NOTE THIS SURVEY CLOSES ON 21 SEPTEMBER 2018

Question Title

* 1. Do you agree that this is an important issue?

Question Title

* 2. Draft NIHR WHO Statement policy
Is the scope of policy right (See policy section 2)

Question Title

* 3. Draft NIHR WHO statement policy 
Section 3. All clinical trials within scope must be registered before the first participant receives an intervention
Do you agree or disagree with the above policy point, and give a brief outline of your reasons below.

Question Title

* 4. Draft NIHR WHO statement policy 
Section 4. Registries should be updated during the study and key outcomes and trial protocol are to be made publicly available within 12 months of study completion
Do you agree or disagree with the above policy point?  Please give a brief outline of your reasons below.

Question Title

* 5. Draft NIHR WHO statement policy 
Section 5. Trial findings should be published in a peer reviewed journal within 24 months from study completion
Do you agree or disagree with the above policy point.  Please give a brief outline of your reasons below.

Question Title

* 6. Draft NIHR WHO statement policy 
Section 6. Past publication and registration practice should be taken into account when reviewing applications for funding for new clinical trials.
Do you agree or disagree with the above policy point?  Please give a brief outline of your reasons below.

Question Title

* 7. Draft NIHR WHO statement policy 
Section 7. Monitoring and reporting on compliance
Do you agree or disagree with the above policy point?  Please give a brief outline of your reasons below.

Question Title

* 8. Draft NIHR WHO statement policy 
Section 8. Individual Participant Data (IPD)
Do you agree or disagree with the above policy point?  Please give a brief outline of your reasons below.

Question Title

* 9. What are the biggest challenges in implementing this policy for the NIHR?

Question Title

* 10. What are the biggest challenges in implementing this policy for the research community?

Question Title

* 11. Are there any unintended consequences of the NIHR implementing this policy?

Question Title

* 12. It would helpful for us to know a little bit about who you are. Are you .....

Question Title

* 13. If you are happy for us to contact you for more information on your feedback please provide your details below: